Alecia Brynda
Critical Care Medicine · Littleton, CONPI 1598004780
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AstraZeneca at 28.7% of the total. 2025 is the largest year on record at $1,160, 8.7 times the $133 reported in 2021.
Across 81 payments — averaging $38.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$886
- Inari Medical, Inc.$293
- Sanofi$246
- GSK$231
- Bayer$173
- Abiomed$170
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,086100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $886 |
| Inari Medical, Inc. | 2 | $293 |
| Sanofi | 10 | $246 |
| GSK | 7 | $231 |
| Bayer | 3 | $173 |
| Abiomed | 2 | $170 |
| Regeneron Healthcare Solutions, Inc. | 5 | $145 |
| United Therapeutics Corporation | 1 | $125 |
| ZOLL Respicardia, Inc. | 1 | $118 |
| Boston Scientific | 2 | $103 |
| Grifols USA, LLC | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $54 |
| Scpharmaceuticals Inc. | 3 | $52 |
| Gilead | 2 | $51 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $49 |
| Amgen | 2 | $48 |
| Merck | 2 | $43 |
| Mylan Specialty L.p. | 1 | $28 |
| Sandoz | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Electromed, Inc. | 2 | $21 |
| Insmed, Inc. | 1 | $21 |
| 3b Medical, Inc. | 1 | $20 |
| Heartflow, Inc. | 1 | $20 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$215
- CT THROMBECTOMY SYSTEM KIT$215
- Impella$145
- TEZSPIRE$125
- Adempas$122
- AIRSUPRA$122
- NUCALA$121
- WAINUA$121
- remede System$118
How this compares
$3,086 in reported general payments places this provider in the 75th percentile of 141 critical care medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 290 | $274,171 |
| EliquisApixaban | 92 | $71,015 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 68 | $64,690 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 87 | $49,938 |
| Breo ElliptaFluticasone/Vilanterol | 68 | $35,896 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 42 | $27,348 |
| Spiriva RespimatTiotropium Bromide | 41 | $23,712 |
| Spiriva HandihalerTiotropium Bromide | 15 | $18,085 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $13,966 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $9,056 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 46 | $6,286 |
| Mycophenolate Mofetil | 36 | $5,668 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 99 | $3,249 |
| Ventolin HfaAlbuterol Sulfate | 30 | $1,731 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $1,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $231 | $360,005445 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $886 | $87,712129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 141 critical care medicine providers in Colorado.
Other critical care medicine in Littleton
- Nitin GuptaLittleton$35K
- Paula McDermottLittleton$34K
- Erin RiggleLittleton$25K
- Kelly GreeneLittleton$18K
- Peter HountrasAurora$86K
- Paul WischmeyerAurora$78K
- Chakradhar KotaruGreenwood Village$61K
- Gregory CosgroveDenver$46K
- Walter ConwellDenver$42K
- David HsiaDenver$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.